PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview

Islam Kourampi (Coresponding Author), Ioannis-Panagiotis Tsetzan, Panagiota Kappi, Nityanand Jain (Coresponding Author)

Research output: Contribution to journalArticlepeer-review

10 Downloads (Pure)


Prostate cancer is the second most common form of cancer in men and the fifth leading cause of death among men worldwide. Men with metastatic castration-resistant prostate cancer (mCRPC) often have BRCA-1 or BRCA-2 gene mutations which can make them sensitive to poly-(ADP-ribose) polymerase inhibitors or PARP inhibitors (PARPi), such as Olaparib, Rucaparib, and Niraparib. Although significant advances have been made with PARPi and the prognosis of patients with mCRPC has improved dramatically, resistance often constitutes a challenge that frequently results in tumor escape. This present communication paper explores the role of PARPi in BRCA-positive prostate cancer and sheds light on numerous published and ongoing clinical trials that will determine the future of PARPi at various tumor stages as a monotherapy or polytherapy regime.
Original languageEnglish
Pages (from-to)40-47
Number of pages8
Issue number1
Publication statusPublished - 19 Jan 2023


  • prostate cancer
  • Parpi
  • BRCA
  • inhibitors
  • treatment
  • resistance

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.4. Reviewed scientific article published in Latvia or abroad in a scientific journal with an editorial board (including university editions)


Dive into the research topics of 'PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview'. Together they form a unique fingerprint.

Cite this